RenaissThera Funding Round

7/2/2026

Venture Equity

Unknown

Seed

The company intends to use the funds to advance its oral small-molecule product pipeline, optimize its lead development assets, and finance preclinical validation tracks to establish Investigational New Drug (IND) regulatory readiness.

Private & Independent

Biopharmaceutical

1st Floor, 7th Main, 9th Cross Road, 2nd Block, Jayanagar 390
Bengaluru, Karnataka, 560011
India

Undisclosed

Not Recorded

Pharmaceutical companies have predominantly concentrated on developing innovative therapies in developed countries, where the cost of development is relatively high, resulting in higher price points that are often unaffordable in many regions globally. This creates a significant delay in access to these novel branded therapies for patients, particularly where insurance coverage is limited. Despite the increasing emphasis on biotech products across various therapy areas, many patients still lack access to these targeted therapies even after generic versions become available, as biosimilars also remain expensive in out-of-pocket settings.